Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 01/06/2004, Updated: 06/04/2007) - This study is testing the ability of modafinil to reduce fatigue in cancer patients who are receiving chemotherapy. The study will also examine the relationship between depression and fatigue in patients treated with modafinil.
Targeted Therapy for Liver or Biliary Tract Cancer
(Posted: 02/21/2006, Updated: 06/04/2007) - In this clinical trial, researchers are testing the ability of a new drug called lapatinib to delay tumor growth and possibly improve the survival of patients with inoperable hepatocellular or biliary tract cancer. Lapatinib works by disrupting chemical signals that stimulate the growth and spread of cancer cells.
Targeted Therapy for Lymphoid Cancers
(Posted: 05/29/2007) - Patients with T-cell or B-cell lymphoid cancers that have recurred or progressed despite prior chemotherapy will receive the drug ABT-263 orally for up to a year in this phase I/II clinical trial.
Monoclonal Antibody Therapy for Treatment-Resistant Blood Cancers
(Posted: 03/29/2005, Updated: 05/16/2007) - This phase I dose-escalation study is investigating safety and tolerability of siplizumab, and will determine the maximum dose that can be given to patients with CD2-positive lymphoproliferative disease.
Romidepsin for T-Cell Lymphoma
(Posted: 01/13/2004, Updated: 05/01/2007) - With this trial, researchers are seeking to determine whether romidepsin (depsipeptide, FR901228), a histone deacetylase inhibitor, can help bring about remission in patients with T-cell lymphoma.